Head And Neck Cancer
Widespread routine thyroid cancer screening can lead to overdiagnosis and overtreatment, the USPSTF contends.
A retrospective evaluation investigated the association between risk of esophageal cancer, metabolic syndrome, Barrett esophagus, and GERD in older persons.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Patients with head and neck cancer treated with IMRT had a significantly shorter duration of feeding tube placement compared with those who received 3DRT.
Transoral robotic surgery (TORS) with or without radiation therapy or chemotherapy is an effective treatment option for patients with oropharyngeal cancer regardless of their p16 status.
Despite a higher risk for HPV-negative orophayngeal squamous cell carcinoma (OPSCC), poor oral health appears to be associated with OPSCC regardless of HPV status.
Gemcitabine in combination with cisplatin is associated with a significant improvement in progression-free survival in nasopharyngeal carcinoma.
Quality of Life and Cosmetic Result of Single-port Access Endoscopic Thyroidectomy via Axillary Approach in Patients with papillary thyroid carcinomaAugust 18, 2016
[OncoTargets and Therapy] This research reviews the effects of single-port access transaxillary totally endoscopic thyroidectomy on outcomes following surgery, including quality of life and cosmetic result, in patients with papillary thyroid carcinoma (PTC).
Patients with medullary thyroid cancer who harbor RET M918T or RAS mutations may derive greater clinical benefit from cabozantinib compared with patients who do not have those genetic mutations.
In contrast of available prospective data, most older patients with locoregionally advanced head and neck cancer are treated with definitive radiotherapy also receive systemic therapy.
Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal CancerAugust 04, 2016
Researchers assessed the rates of laryngeal preservation and laryngectomy-free survival in patients with laryngeal or hypopharyngeal cancer who received the monoclonal antibody cetuximab and radiation therapy or radiation therapy alone.
Methadone appears to be superior to fentanyl for the treatment of neuropathic pain in patients with head and neck cancer.
A recent study examined the possible correlation between Medicaid coverage status and overall survival for patients with head and neck cancer.
There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.
The incidence of oropharyngeal squamous cell carcinoma is increasing among older patients residing in the United States, likely due to the increase in HPV-associated malignancies.
Beverages derived from broccoli sprout extracts were found to have preclinical chemopreventive activity against oral cancer induced by carcinogens.
Quality of life for patients with oral cancer can be dismal due to cancer-related pain. An NIDCR grant is supporting the investigation of a nonviral gene delivery method for treating oral cancer pain safely and effectively.
Scientists developed an innovative nanoplatform to more effectively deliver RNA interference to anaplastic thyroid cancer (ATC) sites. ATC is the most aggressive form of thyroid cancer; mortality is almost 100% and median survival is 3 to 5 months.
Stepped care is effective and reduces recovery time among patients with head and neck cancer or lung cancer and untreated psychological distress.
Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal CancerJune 05, 2016
Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer GI and hematologic toxicities, according to phase 3 trial results presented at the ASCO 2016 Annual Meeting.
Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.
A phase 3 noninferiority study has found that in patients with nonoperable locally advanced squamous cell cancer of the head and neck, concurrent chemoradiotherapy remains the standard treatment, according to results presented at the ASCO 2016 Annual Meeting.
The immunotherapy drug nivolumab conferred a survival benefit in patients with head and neck cancer over standard chemotherapy.
Incorporating a modified MASCC grading tool for evaluating epidermal growth factor receptor inhibitor (EGFRI) toxicities and quality of life improved the rate of skin assessments and documentation.
Oncology Nurse-led Team Can Reduce Treatment Delays, Hospitalizations for Patients With Head and Neck CancerApril 28, 2016
An oncology nurse-led team approach can reduce treatment delays and hospitalizations and improve quality of care for patients with head and neck cancer.
The effectiveness of chemotherapy was enhanced by targeting survivin, a protein that inhibits apoptosis or cell death, according to preclinical research in cells and mouse models of retinoblastoma.
Having an unplanned readmission within 30 days of undergoing definitive surgery is associated with increased risk of 30-day mortality among patients with previously untreated parotid cancer.
In women of reproductive age who have thyroid cancer, their remaining egg supply is affected by radioactive iodine treatment, potentially reducing their fertility.
Patients age 65 years or older with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) did not have worse clinical outcomes.
- Beta-blockers May Improve Survival in Multiple Myeloma
- Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma
- Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC
- Adding Onartuzumab to Chemo Not Effective for HER2-, MET+ Gastroesophageal Adenocarcinoma
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|